Indications & Dose: ENDOMETRIOSIS Mild PO Adult Initially 200-400mg/day in 2 divided doses MD 800mg/day in 2 divided doses to achieve amenorrhea & rapid response to painful symptoms. Continue for 3-6 month (or 9 month) without interruption | FIBROCYSTIC BREAST DISEASE PO Adult 100-400mg/day in 2 divided doses | GYNECOMASTIA PO Adult Initially 400mg/day in 4 divided doses 6 months, max 800mg/day Child 200mg/day in adolescents, may increase to 400mg/day after 2 months if no response occurs. Therapy is given for 6 months | HEREDITARY ANGIOEDEMA PO Adult Initially 200mg BID/TID, after favorable response decrease dose by 50% or less at interval of 1-3 month, if an attack occurs, increase dose to 200mg/day | MENORRHAGIA PO Adult 200mg/day 3 month | PRE-OPERATIVE THINNING OF ENDOMETRIUM PO Adult 400-800mg/day in 4 divided doses 3-6 wk

Precautions: CAD, conditions aggravated by edema, mild-to-moderate hepatic disease, children, seizure, cardiac/renal dysfunction, exclude carcinoma of breast

ADR: Serious: Benign intracranial HTN, thrombotic events, MI, papilledema, pancreatitis, blood disorders, splenic peliosis, peliosis hepatis, hepatic adenoma, malignant hepatic tumor, SJS, hematuria, blurred vision, Others: nausea, vomiting, constipation, indigestion, menstrual cycle disturbances, vaginal dryness, changes in breast size, decreased libido, muscle cramps/spasms/pain/fasciculations, joint pain & swelling, hirsutism, weight gain, edema, deepening of voice, headache, tremor, anxiety, depression, palpitations

DDI: Serious Aminoglutethimide efficacy reduces by drug, Warfarin increases anticoagulant effects, Tacrolimus levels increases by drug, Carbamazepine levels increases markedly & toxicity may occur by drug, Ciclosporin levels increases markedly by drug, Insulin resistance caused by drug

Monitor: Assess for early indications of benignintracranial hypertension, hepatic problems, thromboembolism & thrombophlebitis, CBC with white cell differential, LFTs & kidney function test